Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
DNA-directed DNAP inhibitor
DRUG CLASS:
DNA-directed DNAP inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
cytarabine (99)
CYC682 (0)
cytarabine (99)
CYC682 (0)
›
Associations
(99)
News
Trials
Search handles
@smbenlazar
Search handles
@smbenlazar
Filter by
Latest
9ms
Following lymphodepletion with fludarabine and cytarabine, NKX101 demonstrated clinical activity and tolerability in patients with difficult-to-treat relapsed/refractory AML, supporting its continued study. @CarlosBachier @SarahCannonDocs #leusm #oncology https://t.co/VNl4rWySPK (@OncLive)
9 months ago
Clinical
|
cytarabine • fludarabine IV • NKX101
10ms
#ASCO23 | Poster Kendall Diebold @UABNews discussed findings that 3-day condensed schedule of cytarabine gives earlier hematopoetic recovery and is as safe as standard 5-day schedule. #leusm (@AML_Hub)
10 months ago
cytarabine
10ms
UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIRZATINIB https://t.co/lrgNGIYZpP #EHA23 #AML #leusm (@smbenlazar)
10 months ago
Clinical
|
Venclexta (venetoclax) • cytarabine • azacitidine
11ms
A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT #AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIRZATINIB.. by Juan Miguel Bergua Burgues EHA Library; Jun 08 2023; 387832 https://t.co/lrgNGIYZpP #EHA23 (@smbenlazar)
11 months ago
Clinical
|
Venclexta (venetoclax) • cytarabine • azacitidine
11ms
Dr. Filipa Lynce (@FilipaLynce) presented her phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (#MBC) at the @df_hcc Breast and Gynecologic Cancer Symposium. https://t.co/oLcCGG7UPd (@DFCI_BreastOnc)
11 months ago
Clinical • Metastases
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
|
Lynparza (olaparib) • sapacitabine (CYC682)
11ms
Fantastic talk by @FilipaLynce on new data from a phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer. Important insights into mechanisms of response. @DFCI_BreastOnc @DanaFarberBRCA (@JennGuerriero)
11 months ago
Clinical • P1 data • Metastases
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
|
Lynparza (olaparib) • sapacitabine (CYC682)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login